Biden to meet U.S. vaccine adviser amid surge, supply problems
The chief adviser for United States (U.S.) efforts to develop a coronavirus vaccine, Moncef Slaoui, said yesterday he planned to meet with President-elect Joe Biden this week to discuss the programme before the expected first round of vaccinations in the country later this month.
Slaoui, chief adviser to the U.S. government’s Operation Warp Speed initiative, said he has not yet met with Biden, who last week criticised the Trump administration’s vaccine distribution plan.
“We really look forward to it because actually things have been really very appropriately planned,” Slaoui said in an interview with CBS’ “Face the Nation.”
Biden said on Friday his team had not seen a detailed outline from the Trump administration to distribute a vaccine to various states, which he called an expensive and difficult process.
“There is no detailed plan that we’ve seen, anyway, as to how you get the vaccine out of a container, into an injection syringe, into somebody’s arm,” Biden said.
Slaoui said part of the confusion may be that the government’s plan relies on state health agencies to deliver the vaccine.
“I think the plans are there and I feel confident that once we will explain it, everything in detail. I hope the new transition team will understand that things are well planned,” he told the CBS program.
The United States is struggling with a resurgence of the virus, with record infections and a daily death toll that has exceeded 2,000 in recent days. More than 281,000 Americans have died from the COVID-19 disease, according to a Reuters tally.
President Donald Trump’s refusal to acknowledge his loss to Biden in the Nov. 3 presidential election caused a delay in the transition process that allowed White House health advisers to communicate with the new Biden health advisory team.
Biden was due to announce members of his public health team this week.
First-responders, health care workers and nursing home residents will be the first groups to receive the vaccine once the U.S. Food and Drug Administration approves it, which is expected in the next week or two. The FDA’s outside advisers are scheduled to meet on Thursday to review Pfizer’s emergency use application for its vaccine
Slaoui has said the second tranche of people to get the vaccine will likely include essential employees such as postal workers, and then the general population will follow.
Asked yesterday when Americans would start seeing the impact of the vaccine, Slaoui told CBS that might happen for the most susceptible people in January or February.
“But on a population basis, for our life to start getting back to normal, we’re talking about April or May,” he said.
Dr. Deborah Birx, who serves with Azar on the White House coronavirus task force, told NBC’s “Meet the Press” that public health officials have had to battle incorrect messages from the Trump administration about masks and other mitigation measures.
Post Comment